Ikarian Capital, LLC Argenx Se Put Options Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $26.5 Million - $39.5 Million	78,100 New	78,100 $29.7 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $47.6 Million - $55.8 Million	132,100 New	132,100 $51.5 Million
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $8.87 Million - $11 Million	-34,500 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$268.3 - $380.31 $44.8 Million - $63.5 Million	-167,000 Reduced 82.88%	34,500 $9.5 Million
Q4 2020 Feb 12, 2021	BUY	$248.13 - $308.36 $49.8 Million - $61.9 Million	200,700 Added 25087.5%	201,500 $59.3 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $26.9 Million - $34.1 Million	-125,000 Reduced 99.36%	800 $209,000
Q1 2020 May 15, 2020	BUY	$108.83 - $165.23 $13.7 Million - $20.8 Million	125,800 New	125,800 $16.6 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.